证券代码：002603 证券简称：以岭药业 公告编号：2025-025 石家庄以岭药业股份有限公司 石家庄以岭药业股份有限公司（以下简称"公司"）于 2025 年 7 月 9 日收 到国家药品监督管理局核准签发的《受理通知书》。现就相关事项公告如下： 一、受理通知书基本内容 申 请 人：石家庄以岭药业股份有限公司 申请事项：境内生产药品注册上市许可 产品名称：半夏白术天麻颗粒 二、药品的基本情况 半夏白术天麻颗粒是公司申报注册的第一个经典名方品种，品种处方为国家 中医药管理局 2018 年 4 月发布的《古代经典名方目录（第一批）》中的第 81 首 处方，出自清代程国彭《医学心悟》，其功能主治为：化痰熄风，健脾祛湿。用 于风痰上扰证。症见眩晕，头痛，胸膈痞闷，恶心呕吐，舌苔白腻，脉弦滑。 关于收到药品注册申请受理通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 受 理 号：CXZS2500028 主要结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 特此公告。 石家庄以岭药业股份有限公司 董事会 2025 年 7 月 ...

Core Viewpoint - Shijiazhuang Yiling Pharmaceutical has received clinical trial approval for its innovative drug G201-Na, targeting the challenge of premature ovulation in assisted reproduction, marking a significant step in the company's expansion into multiple therapeutic areas [1][3][4]. Group 1: Company Strategy and Development - The approval of G201-Na represents a crucial foundation for Yiling's pharmaceutical portfolio and reflects its ambition to diversify beyond traditional Chinese medicine [3]. - The company has established a three-step strategy: "transfer processing - generic drugs - patented new drugs," which has strengthened its pharmaceutical foundation over the years [7]. - Yiling has successfully obtained 13 ANDA approvals in Europe and the US, and its production lines have passed GMP certifications in multiple countries, positioning it among the top 30 in China's pharmaceutical industry in 2023 [7]. Group 2: Market Potential and Competitive Advantage - G201-Na addresses a key pain point in the multi-billion dollar assisted reproduction market, with the potential for significant market impact [5]. - The upcoming 2024 Clinical Application Planning for Assisted Reproductive Technology is expected to expand reproductive centers, supported by ongoing population policies, indicating a potential breakthrough in the domestic ART market [11]. - The current GnRH antagonist market is primarily dominated by imported drugs, presenting a substantial opportunity for domestic alternatives [11]. Group 3: Innovation and Research - Yiling's dual-track innovation strategy combines traditional Chinese medicine with chemical drug innovation, providing a robust foundation for its growth [10][14]. - The company has a strong clinical resource base in gynecology, with existing products facilitating patient recruitment for new drug trials, enhancing market access post-launch [11]. - The company emphasizes the importance of solid theoretical research and strong industrial capabilities in balancing traditional and innovative approaches [14].

Group 1 - Xinhua Medical's subsidiary has received a Class II medical device registration certificate for its thoracic and abdominal endoscope, enhancing its product offerings in minimally invasive surgery [1] - The successful registration of the thoracic and abdominal endoscope enriches Xinhua Medical's portfolio and creates new market growth opportunities [1] Group 2 - Sino-Pharmaceutical has signed a joint research and licensing agreement with Gero PTE to develop new therapies for age-related diseases, involving potential payments of up to $250 million [2] - The collaboration reflects significant market interest and investment potential in the field of age-related disease treatments, combining Gero's AI-driven technology with Sino-Pharmaceutical's resources [2] Group 3 - Yiling Pharmaceutical's G201-Na capsule, a new chemical drug for controlling ovulation in assisted reproductive technology, has received approval for clinical trials [3] - The approval marks a significant breakthrough in Yiling Pharmaceutical's drug development, targeting a market with substantial potential [3] Group 4 - Hainan Haiyao plans to accept financial support from its controlling shareholder, with a maximum amount of RMB 500 million, to stabilize operations and enhance market confidence [4] - The financial assistance, with an annual interest rate of 5%, will be used for the company's main business and to supplement working capital [4]

证券代码：002603 证券简称：以岭药业 公告编号：2025-023 特此公告。 关于提前归还补充流动资金的募集资金的公告 石家庄以岭药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）于 2024 年 7 月 8 日分别 召开第八届董事会第十二次会议和第八届监事会第七次会议，审议通过了《关于 使用部分闲置非公开发行募集资金暂时补充流动资金的议案》，决定使用 2017 年 非公开发行募集资金项目部分闲置资金不超过人民币39,000万元暂时补充流动资 金，使用期限为自董事会批准之日起不超过 12 个月。相关公告详见刊登于 2023 年 7 月 8 日《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯网 (www.cninfo.com.cn) 的《关于使用部分闲置非公开发行募集资金暂时补充流动资 金的公告》（公告编号 2024-024）。 2025 年 4 月 25 日，公司已将 22,000 万元资金提前归还并存入公司募集资金 专用账户，详见公司于 2025 年 4 月 26 日披露的《关 ...

证券代码：002603 证券简称：以岭药业 公告编号：2025-024 石家庄以岭药业股份有限公司 关于化药创新药"G201-Na 胶囊"临床试验申请 申请事项：新药临床试验 受 理 号：CXHL2500424，CXHL2500425 申 请 人：石家庄以岭药业股份有限公司 获得批准的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日收到 国家药品监督管理局核准签发的《药物临床试验批准通知书》，现将相关情况公 告如下： 一、临床试验申请及批准通知书主要内容 药物名称：G201-Na 胶囊 注册分类：化学药品 1 类 适 应 症：辅助生殖技术（ART）中，用于控制性超促排卵治疗的患者，防 止提前排卵 剂 型：胶囊剂 主要审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 2025 年 4 月 29 日受理的 G201-Na 胶囊临床试验申请符合药品注册的有关要求， 建议批准本品开展临床试验。申请的适应症：辅助生殖技术（ART）中，用于控 制性超促排卵治疗的患者，防止提前 ...

Market Overview - The US stock market was closed on July 4th for Independence Day [1] Hong Kong Stock Market Highlights - Yum China (09987) rose over 3% after announcing the establishment of an innovation fund to convert operational needs into practical applications [2] - H&H International Holdings (01112) fell over 7%, expecting a 45% to 65% decline in net profit for the first half of the year [2] - China Rare Earth Holdings (03788) surged nearly 9% as it plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Health Road (02587) jumped over 18% as its controlling shareholder voluntarily extended the lock-up period, focusing on digital health services [2] - Smoore International (06969) increased over 5% with the launch of Glo Hilo in Japan, maintaining high profit margins [2] - Tencent Music (01698) rose nearly 3% as institutions noted that recent acquisition plans would enhance overall content supply [2] - Jihong Co., Ltd. (02603) surged over 7%, with a projected net profit increase of over 55% year-on-year for the first half [2] - Solar stocks collectively declined, with Xinyi Solar (00968) down 4.86%, Fuyao Glass (06865) down 3.88%, New Energy (01799) down 3.19%, and Xinyi Glass (00868) down 2.64% [2] Other Notable Movements - Kuaishou-W (01024) rose over 3% as it plans to launch a live streaming initiative across multiple cities to create a collaborative ecosystem [3] - Gold stocks faced pressure, with Shandong Gold (01787) down 5.09%, China Gold International (02099) down 3.44%, Lingbao Gold (03330) down 2.68%, and Chifeng Jilong Gold (06693) down 2.33% [3] - China Shipbuilding Defense (00317) increased over 3% after the approval of a merger and acquisition restructuring plan, optimizing resources in the shipbuilding industry [3] - Medical device stocks saw a broad increase, with Spring Medical (01858) up 6.36%, Yongsheng Medical (01612) up 7.27%, Xinwei Medical-B (06609) up 3.55%, and Microneuroscience (02172) up 1.12% [3] - Some stablecoin concept stocks rose, with Victory Securities (08540) up 6.9%, Guotai Junan International (01788) up 5.15%, Yika (09923) up 2.59%, and China Everbright Holdings (00165) up 1.96% [3] - SF Express City (09699) rose nearly 7% amid intensified competition in the food delivery sector, with expectations of increased order volume [3] - HSSP International (03626) fell over 20% after being named by the Hong Kong Securities and Futures Commission for high stock concentration [3] Strategic Partnerships and New Listings - Shengye (06069) opened nearly 15% higher after forming a strategic partnership with Stand Robot to enhance its robotics industry chain [4] - Beverage stocks opened high, with Cha Bai Dao (02555) up 15%, Nayuki's Tea (02150) up 9.87%, Gu Ming (01364) up 5.77%, Hu Shang Ayi (02589) up 2.99%, and Mixue Group (02097) up 2.92% [4] - FWD Group (01828) had a flat opening on its first day of listing, being a life insurance company under Li Zeqiang's control [4]

Market Performance - The market experienced an upward trend last week, with the CSI Xinhua National Brand Index rising by 1.39% to 1649.96 points [1][2] - The Shanghai Composite Index increased by 1.40%, the Shenzhen Component Index by 1.25%, the ChiNext Index by 1.50%, and the CSI 300 Index by 1.54% [2] Strong Stock Performances - Notable strong performers included Anji Technology, which rose by 7.98%, and WuXi AppTec, which increased by 7.58% [2] - Other significant gainers included Yiling Pharmaceutical, Tiger Med, and AVIC Shenyang Aircraft, all rising over 6% [2] - The overall trend showed many stocks in the index gaining over 1%, indicating broad market strength [2] Year-to-Date Performance - Since the beginning of 2025, notable stock performances include: - Xintai rising by 55.34% - Anji Technology increasing by 45.75% - WuXi AppTec and Marubi both rising over 30% [3] Market Outlook - Analysts from Xing Shi Investment suggest that the market will continue to perform positively due to strong trading sentiment and sector rotation opportunities [4] - The overall risk premium in the A-share market remains at historically low levels, indicating high value [4] - The macroeconomic environment is expected to remain stable, with ongoing domestic policy support and emerging opportunities in sectors like artificial intelligence and new consumption [4][5] Investment Strategy - Wangzheng Asset maintains a strategy focused on "technology blue chips + innovative growth," emphasizing quality of business operations and undervalued stocks in sectors such as internet, electronics, and automotive [5] - The focus is also on high-potential innovative growth sectors as they mature and enter rapid growth phases [5]

Core Viewpoint - The severe flooding in Rongjiang County, Guizhou Province, has significantly impacted local residents' lives and posed challenges for flood relief and post-disaster public health protection. In response, Yiling Health Technology has donated health supplies to support relief efforts [1][3]. Group 1: Company Response - Yiling Health Technology donated 38,400 cans of Lianhua Qingfei plant beverage and 30,000 Lianhua Baozhu masks to the flood-affected area to aid in flood relief and health protection efforts [1][3]. - The donated Lianhua Qingfei plant beverage provides refreshing hydration for rescue workers and affected residents, while the masks help reduce the risk of disease transmission in the disaster area [3]. - A representative from Yiling Health emphasized the company's commitment to social responsibility and the importance of supporting affected communities during crises [3]. Group 2: Corporate Philanthropy - Yiling Health has a long-standing commitment to public welfare, having donated over 20 million yuan worth of health supplies to the Chinese Red Cross during the COVID-19 pandemic, supporting both domestic and international efforts [5]. - In 2021, Yiling Health launched the "Lianhua Respiratory Health Public Welfare Action" project, donating 50 million yuan in funds and materials for pandemic prevention and flood relief [5]. - The recent support for the Rongjiang disaster area is seen as a continuation of the company's philanthropic practices [5]. Group 3: Ongoing Commitment - Yiling Health will continue to monitor the disaster situation and fully support flood relief efforts, expressing confidence in the community's ability to rebuild [6].

Core Viewpoint - Yiling Pharmaceutical is actively promoting the internationalization of traditional Chinese medicine (TCM) as a necessary evolution for survival and development in a competitive market [5][12]. Group 1: Company Growth and Internationalization - Yiling Pharmaceutical has expanded its presence to over 50 countries and regions, including Southeast Asia, North America, the Middle East, Africa, Eastern Europe, and South America [3]. - The company has been recognized as one of the "Top 100 Chinese Brand Values," "Top 20 Chinese Pharmaceutical Listed Companies," and "Top 10 Chinese Traditional Chinese Medicine Enterprises," reflecting its growth and competitiveness on the global stage [3]. - The company has established over 60 planting bases for authentic medicinal materials across more than 20 provinces in China to ensure product quality from the source [5]. Group 2: Innovative Research and Development - Yiling Pharmaceutical has developed a five-in-one operational model that integrates theory, clinical practice, research, industry, and education to foster a robust innovation ecosystem [5]. - The company collaborates with international research institutions, including Cardiff University, Leiden University, Harvard Medical School, and Duke University, conducting over 40 high-standard evidence-based medical studies and publishing more than 300 SCI papers [7][9]. - The establishment of the "Luo Disease Theory" framework has garnered significant attention and six national-level science and technology awards, enhancing the company's reputation in the industry [8][9]. Group 3: Market Expansion Strategies - Yiling Pharmaceutical employs a "dual-line parallel" strategy to navigate the complexities of international markets, focusing on academic promotion and tailored marketing strategies based on regional characteristics [12][14]. - The successful internationalization of the Lianhua Qingwen Capsule, which has become a staple in Thai households, exemplifies the company's effective market penetration strategies [15]. - The company aims to make its products accessible in chain pharmacies and supermarkets, targeting high-traffic demographics such as office workers and tourists [15]. Group 4: Future Aspirations - Yiling Pharmaceutical envisions becoming an influential innovative brand in the global TCM sector, emphasizing that internationalization is a new starting point rather than an endpoint [16].

Group 1 - The 2025 PDI Pharmaceutical R&D and Innovation Conference highlighted key themes such as innovative drug development, antibody drugs, clinical development technology, and traditional Chinese medicine innovation [1] - Yiling Pharmaceutical (002603.SZ) ranked second in the 2025 China Traditional Chinese Medicine R&D Strength Ranking, showcasing its excellence in TCM research [1] - Founded in June 1992, Yiling Pharmaceutical focuses on the R&D, production, and sales of patented innovative TCM, while also expanding into biopharmaceuticals and health industries [1] Group 2 - Yiling Pharmaceutical has invested approximately 5 billion yuan in R&D over the past five years, maintaining a leading position in the industry [2] - The company holds 17 patented TCM products covering eight major clinical disease systems, with significant advancements in cardiovascular and respiratory disease medications [2] - Yiling Pharmaceutical has received multiple national and provincial research project awards, including one first-class and four second-class National Science and Technology Progress Awards, and has over 400 TCM invention patents [2] Group 3 - Looking ahead, Yiling Pharmaceutical aims to strengthen its unique position among leading companies through theoretical innovation, comprehensive industry chain layout, high R&D investment, and international practices [2] - The company plans to optimize its cost structure, expand its range of indications, and continuously develop new products to enhance its competitive advantage in the market [2]